Open AccessSpironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion
Author(s) -
Gabriela de Cássia Sousa Amâncio,
Milla Marques Hermidorff,
Ana Cláudia Alvarenga Carneiro,
Wanderson Geraldo de Lima,
Homero Nogueira Guimarães,
Henrique Resende Rodrigues,
Emília Calil Silva,
Leonardo Vinícius Monteiro de Assis,
Andrea GrabeGuimarães,
Mauro César Isoldi
Publication year - 2022
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v11i3.26498
Subject(s) - eplerenone , spironolactone , medicine , cardiology , myocardial infarction , ligation , aldosterone , mineralocorticoid receptor , adrenalectomy , qt interval , coronary occlusion , anesthesia
Mineralocorticoid receptor antagonists (MRAs) are effective in reducing left ventricle remodeling and sudden death after acute myocardial infarction (AMI). Objectives: MRAs in vitro display cardioprotective effects, independent of MR; however, it is unknown whether the rapid effects of MRAs are cardioprotective in vivo. This study evaluated the acute effects of spironolactone and eplerenone in the first minutes of AMI. Methods: Wistar Rats, submitted or not to bilateral adrenalectomy, were treated orally with spironolactone (20 mg/kg) or eplerenone (10 mg/kg), and submitted to the left coronary ligation, under anesthesia. Electrocardiogram (ECG) recordings were obtained to evaluate ST-T segment, QT, and QTc intervals. Arterial pressure was also measured before (baseline) and after coronary ligation. Results: Spironolactone or eplerenone given, one hour before coronary ligation, prevented ST-T segment elevation in adrenalectomized and non-adrenalectomized. QT interval analysis showed that MRAs prevented its prolongation after coronary ligation. QT and QTc intervals remained similar to baseline and were smaller than the values displayed by the non-treated group. Animals treated with spironolactone, regardless of adrenalectomy, showed a 3-fold reduced mortality rates compared to the control group. Conclusion: MRAs display acute cardioprotective effects in early phase of AMI, which are independent of aldosterone.